Mortiz A J, Kunz C, Hofman H, Liehl E, Reeve P, Maassab H F
J Infect Dis. 1980 Dec;142(6):857-60. doi: 10.1093/infdis/142.6.857.
A cold-recombinant influenza A virus, CR 22, derived from A/Ann Arbor/6/60 (H2N2) cold-adapted virus and A/Victoria/3/75 (H3N2) wild-type virus, was tested in adult volunteers. CR 22 induced only low-grade clinical reactions in volunteers who had low titers of serum antibodies. Virus could be reisolated from about one-third of the volunteers, but only at low titers. No revertant viruses were found, and there was no evidence for transmission of virus to unvaccinated volunteers housed in the close contact with the vaccinees. A high proportion of the volunteers seroconverted, and the mean titers of serum antibody after immunization suggest that a high degree of protection is induced by vaccination with liver CR 22 virus.
一种冷重组甲型流感病毒CR 22,它源自A/安阿伯/6/60(H2N2)冷适应病毒和A/维多利亚/3/75(H3N2)野生型病毒,在成年志愿者身上进行了测试。CR 22在血清抗体滴度较低的志愿者中仅引发了轻度临床反应。病毒能从约三分之一的志愿者体内重新分离出来,但滴度较低。未发现回复突变病毒,也没有证据表明病毒传播给了与接种者密切接触的未接种疫苗的志愿者。很大比例的志愿者发生了血清转化,免疫后血清抗体的平均滴度表明,接种CR 22肝病毒可诱导高度的保护作用。